CERE
Overvalued by 93% based on the discounted cash flow analysis.
Market cap | $8.19 Billion |
---|---|
Enterprise Value | $8.24 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-2.67 |
Beta | 1.41 |
Outstanding Shares | 181,610,675 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -17.73 |
---|---|
PEG | -66.94 |
Price to Sales | - |
Price to Book Ratio | 14.99 |
Enterprise Value to Revenue | 998.77 |
Enterprise Value to EBIT | -17.27 |
Enterprise Value to Net Income | -18 |
Total Debt to Enterprise | 0.04 |
Debt to Equity | 0.65 |
No data
No data
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focu...